Ocular Therapeutix seeks second indication for drug-delivery eye insert

Ocular Therapeutix (NSDQ:OCUL) said yesterday that it submitted a supplement NDA to the FDA for its dexamethasone ocular insert, Dextenza.
The Bedford, Mass.-based company requested that the U.S. regulatory agency expand the current indication for Dextenza to include the treatment of ocular inflammation following eye surgery.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix seeks second indication for drug-delivery eye insert appeared first on MassDevice.

Source: Mass Device - January 11, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat oculartherapeutix Source Type: news